AbbVie inks Humira patent deal No. 7 with Pfizer by Eric Sagonowsky Friday, November 30, 2018 Following a handful of deals for other biosimilar drugmakers, Pfizer decided to settle its Humira patent fight with AbbVie.
Samsung BioLogics hits back against Korean regulators by Arlene Weintraub Wednesday, November 28, 2018 Samsung is fighting back against charges that it improperly changed the method by which it valued a joint venture with Biogen.
AbbVie strikes Humira patent deal with Fresenius Kabi by Eric Sagonowsky Thursday, October 18, 2018 In a Humira patent deal with AbbVie, Fresenius Kabi will have to pay undisclosed royalties and can launch its biosim in Europe upon approval.
Roche sets up patent hurdle for Herceptin biosimilar: analyst by Eric Palmer Monday, September 10, 2018 Roche is battling competition from Herceptin biosimilars and has reportedly sued Bioepis over its biosimilar as it heads for the finish line.
FiercePharmaAsia—Lenvima, China’s drug invite, Samsung and more by Angus Liu Friday, August 10, 2018 Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.
Biogen to spend $700M to build stake in Samsung biosims JV by Eric Sagonowsky Friday, June 29, 2018 Biogen will pay about $700 million to boost its stake in Samsung Bioepis to 49.9%. It currently owns 5.4% of the biosimilars joint venture.
Biogen to boost stake in biosims joint venture: CFO by Eric Sagonowsky Friday, April 27, 2018 Ahead of a big launch this fall, Biogen says it plans to increase its stake in a biosimilars joint venture shared with Samsung.
Novartis CEO calls for simpler biosim rules, end to rebate wall by Eric Sagonowsky Friday, April 13, 2018 Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.
AbbVie's Humira wins another biosim reprieve with Biogen deal by Eric Sagonowsky Thursday, April 5, 2018 AbbVie shielded Humira from another U.S. biosims threat in a deal that makes it "increasingly unlikely" any copycats will launch here before 2023.
Pharma's pervasive 'evergreening' driving prices up, study says by Eric Sagonowsky Friday, November 3, 2017 New research takes a wide look at the strategy of "evergreening," or adding new patents to extend a drug's exclusivity.
